Spatial autophagy failure as a pharmacodynamic endpoint for autophagy-targeted dermatological interventions

Autophagy-modulating dermatological interventions include topical, intralesional and systemic therapies, defined bioactive molecules and nutraceutical candidates. Their effects are commonly evaluated using tissue-averaged LC3-II, p62/SQSTM1 and canonical pathway markers. Although these measures support assessment of autophagy pathway engagement, they may miss spatially restricted pharmacodynamic non-response and cannot determine whether persistent local dysfunction reflects inadequate exposure or biology-limited non-response. Here we propose spatial autophagy failure (SAF) as a spatial pharmacodynamic endpoint for autophagy-targeted dermatological interventions. SAF denotes contiguous skin domains showing evidence of impaired autophagic processing and lysosomal dysfunction relative to adjacent tissue. We use photoaged skin and melanophagy as the principal test case. In this setting, persistent hyperpigmented hotspots may partly reflect localized defects in melanosome clearance alongside altered melanogenesis and melanosome transfer. Chronic wounds and pathological scars provide additional contexts in which spatially heterogeneous autophagic capacity may influence treatment response. SAF assessment integrates local drug exposure, local target or pathway engagement, autophagy-lysosome readouts and phenotype maps, distinguishing exposure-limited from biology-limited non-response. Treatment effects can be quantified using total SAF burden, largest-zone size (expressed as area in two-dimensional sections or volume in three-dimensional models), zone contiguity and distance to the nearest phenotype-associated region. These spatial endpoints may inform lead selection, formulation and route optimization, dose and schedule selection and pharmacodynamic monitoring. The framework reframes the central questions: Does an intervention merely shift autophagy markers on average? More importantly, does adequate local exposure produce local target or pathway engagement, restore autophagic processing and improve the corresponding local phenotype?

Authors

Institutions

Publication Details

Journal
Pharmacological Research
Published
2026-09-01
DOI
https://doi.org/10.1016/j.phrs.2026.108422
Primary Topic
Autophagy in Disease and Therapy
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Spatial autophagy failure as a pharmacodynamic endpoint for autophagy-targeted dermatological interventions

Chang Hyung Lee, Ki Won Lee
Pharmacological Research
Autophagy in Disease and Therapy
article

Spatial autophagy failure as a pharmacodynamic endpoint for autophagy-targeted dermatological interventions

Chang Hyung Lee, Ki Won Lee
article en

Abstract

Autophagy-modulating dermatological interventions include topical, intralesional and systemic therapies, defined bioactive molecules and nutraceutical candidates. Their effects are commonly evaluated using tissue-averaged LC3-II, p62/SQSTM1 and canonical pathway markers. Although these measures support assessment of autophagy pathway engagement, they may miss spatially restricted pharmacodynamic non-response and cannot determine whether persistent local dysfunction reflects inadequate exposure or biology-limited non-response. Here we propose spatial autophagy failure (SAF) as a spatial pharmacodynamic endpoint for autophagy-targeted dermatological interventions. SAF denotes contiguous skin domains showing evidence of impaired autophagic processing and lysosomal dysfunction relative to adjacent tissue. We use photoaged skin and melanophagy as the principal test case. In this setting, persistent hyperpigmented hotspots may partly reflect localized defects in melanosome clearance alongside altered melanogenesis and melanosome transfer. Chronic wounds and pathological scars provide additional contexts in which spatially heterogeneous autophagic capacity may influence treatment response. SAF assessment integrates local drug exposure, local target or pathway engagement, autophagy-lysosome readouts and phenotype maps, distinguishing exposure-limited from biology-limited non-response. Treatment effects can be quantified using total SAF burden, largest-zone size (expressed as area in two-dimensional sections or volume in three-dimensional models), zone contiguity and distance to the nearest phenotype-associated region. These spatial endpoints may inform lead selection, formulation and route optimization, dose and schedule selection and pharmacodynamic monitoring. The framework reframes the central questions: Does an intervention merely shift autophagy markers on average? More importantly, does adequate local exposure produce local target or pathway engagement, restore autophagic processing and improve the corresponding local phenotype?

Pharmacological Research
Seoul National University of Science and Technology (KR), Harvard University (US), Seoul National University (KR), Advanced Institute of Convergence Technology (KR), Sungkyunkwan University (KR)
National Research Foundation, Kyungpook National University, National Research Foundation of Korea, Ministry of Science and ICT, South Korea
Openalex Percentile: Top 10%
Autophagy in Disease and Therapy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.